What is Emit Imaging?
Emit Imaging operates at the intersection of advanced optics and molecular biology, specializing in Cryo-Fluorescence Tomography (CFT). The company's flagship platform, Xerra, represents a paradigm shift in preclinical imaging, enabling automated, high-resolution visualization of drug distribution and protein expression. By providing both sophisticated instrumentation and specialized fee-for-service research capabilities through its Boston and Baltimore facilities, Emit Imaging serves a critical function in the drug discovery, oncology, and gene therapy pipelines. Their technology effectively bridges the gap between traditional imaging limitations and the complex requirements of modern neuroscience and therapeutic research, establishing the company as a vital partner for pharmaceutical and academic institutions alike.
How much funding has Emit Imaging raised?
Emit Imaging has raised a total of $7.1M across 1 funding round:
Private Equity
$7.1M
Private Equity (2025): $7.1M, investors not publicly disclosed
Key Investors in Emit Imaging
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Emit Imaging?
With this recent infusion of capital, Emit Imaging is poised to scale its operational footprint and enhance its R&D capabilities. The strategic roadmap likely involves expanding the reach of the Xerra platform into broader global markets and deepening its service offerings in high-demand therapeutic areas. As the company transitions into this next phase of growth, the focus will remain on optimizing workflow automation and maintaining its competitive edge in the high-resolution imaging landscape. By scaling its laboratory infrastructure and refining its technological stack, Emit Imaging is well-positioned to capitalize on the increasing demand for precise, data-driven insights in the preclinical research sector, ultimately accelerating the path from discovery to clinical application.
See full Emit Imaging company page
